Glencet tablets 5 mg. №30

Description

Glencet Storage:

active substance: levosetirizine

1 tablet contains levocetirizine dihydrochloride 5 mg

Excipients: lactose monohydrate cellulose microcrystalline silicon dioxide colloidal anhydrous magnesium stearate Opadry white (Opadry Y 1-7000): titanium dioxide (E 171) polyethylene glycol hypromellose.

Glencet Dosage form.

The tablets are coated.

Main physical and chemical properties: white oval biconvex tablets are coated with a fracture line on one side and a smooth surface on the other side with the inscription G on both sides of the fracture line.

Glencet Pharmacotherapeutic group.

Antihistamines for systemic use. Piperazine derivatives.

ATX code R06A E09.

Pharmacological properties.

Pharmacodynamics.

1-histamine receptors. The affinity for H1-histamine receptors in levocetirizine is 2 times higher than in cetirizine. Affects the histamine-dependent stage of the allergic reaction reduces the migration of eosinophils vascular permeability limits the release of inflammatory mediators. Prevents the development and facilitates the course of allergic reactions has antiexudative antipruritic anti-inflammatory action has virtually no anticholinergic and antiserotonin action.

Clinical characteristics.

Indication.

Symptomatic treatment of allergic rhinitis, including perennial allergic rhinitis and urticaria.

Contraindication.

Hypersensitivity to levocetirizine or to any other component of this dosage form or to any piperazine derivatives.

Rare inherited diseases galactose intolerance lactase deficiency or impaired absorption of glucose and galactose.